Article Text

Download PDFPDF

PO.1.4 The eIF4 translational inhibitor pateamine a improves immunological and neurological functions in BXSB.Yaa lupus mice
  1. G Gómez-Hernández1,
  2. N Varela1,
  3. H Bagavant2,
  4. G Barturen1,
  5. M Alracón-Riquelme1 and
  6. M Morell1
  1. 1GENYO. Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government ~ Granada ~ Spain
  2. 2Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, USA ~ Oklahoma ~ USA


Purpose In this work we analyzed the therapeutic potential of a natural compound, Patemine A (PatA) to treat SLE. Pat A is an inhibitor of the eIF4 complex, involved in the translation initiation process, with immunosuppressive properties that has been tested successfully in cancer mouse models.

Methods To evaluate Pat A efficiency in SLE we used the BXSB.Yaa lupus model. In this strain the presence of Yaa in males results in autoimmune disease manifestations, renal failure, and a mortality rate of 60% by 20 weeks of age. BXSB.Yaa males were treated with PatA administered intraperitoneally 3 times per week for 8 weeks starting at the initial stage of disease (12 weeks). Sera was collected every three weeks to follow disease progression and at final point (20 weeks) we performed serological analysis (cytokines and autoantibodies), flow cytometry on spleen, kidney histological and functional assays and behavioral tests to evaluate neurological signs of the disease.

Results Pat A treatment increased survival rates and reduced circulating levels of proinflammatory cytokines and autoantibodies in the BXSB.Yaa lupus model. Kidney function was also improved in the animal that received Pat A with no major changes at the histological level. Treated mice also showed an improvement on cognitive function (learning/memory, and depression) together with a reduction of proinflammatory cytokines locally in the hippocampus.

Conclusions These data suggest that translation inhibition improves disease signs at the immunological and neurological level opening a new line of research based on translation inhibition to treat lupus and other autoimmune diseases.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.